Business Context and Reporting Period
Company: InflaRx N.V.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: May 17, 2018
Reporting Period: The filing incorporates by reference Unaudited Condensed Consolidated Financial Statements and Management's Discussion and Analysis for the three months ended March 31, 2018.
Key Financial Metrics
The provided text is a cover sheet and exhibit index for Form 6-K. It does not contain the actual financial data. Specific values for revenue, profit, cash flow, margins, debt, and liquidity are not present in this excerpt; they are located in the referenced Exhibits 99.1 and 99.2.
Material Changes
The filing text does not provide specific details regarding material changes versus prior periods. Such analysis is contained within the incorporated Management's Discussion and Analysis (Exhibit 99.2).
Guidance, Outlook, and Risks
The filing incorporates a Press Release dated May 17, 2018 (Exhibit 99.3), which likely contains management commentary and outlook, but the text of the release is not included in the provided input. No specific risks or contingencies are detailed in this cover document.
Investor Verification Checklist
- Review Exhibit 99.1 for the actual Unaudited Condensed Consolidated Financial Statements for the quarter ended March 31, 2018.
- Examine Exhibit 99.2 for Management's Discussion and Analysis to understand operational results and financial condition.
- Read Exhibit 99.3 (Press Release) for any strategic updates, clinical trial progress, or forward-looking statements.
- Verify the incorporation by reference into the Form S-8 registration statement (No. 333-221656).